Perspectives on Life Sciences
202 total results. Page 1 of 9.
IP Partner Pamela M. Deese is a featured speaker at the Brand Protection Summit, co-hosted by CounterFind and Warner Music Group on November 7th, 2019 in New York.
Twenty-five Arent Fox LLP practices have been recognized in the 2020 “Best Law Firms” rankings that are published annually by US News & World Report and Best Lawyers.
The protection of intellectual property in the biotech industry is critical. Patents are the most common form of IP protection for biotech inventions.
Life Sciences Counsel Brian Malkin is the keynote speaker of the Michigan Institute for Clinical & Health Research’s Medical Devices in Academic Research Symposium on October 16, 2019. Brian will also moderate a panel discussion during the event.
Counsel Brian Malkin will speak on a panel about FDA’s role in the regulation of cannabis at the Food and Drug Law Institute Legal and Practical Issues in the Evolving World of Cannabis Regulation conference on November 18-19, 2019.
Life Sciences Counsel Brian Malkin will speak at AdvaMed’s Investigational Device Exemption (IDE) Submissions Workshop in Washington, DC on October 9.
WASHINGTON — Fifty Arent Fox LLP attorneys have been rated as leaders in their profession by The Best Lawyers in America 2020.
Life Sciences Partner Karen Ellis Carr will speak at the Farm Foundation® Forum, “Gene Editing: Opportunities and Challenges,” at the National Press Club on July 17, 2018.
Arent Fox Expands Food, Drug, Medical Device & Cosmetic Practice with Addition of Partner Deborah M. Shelton
Arent Fox LLP is pleased to announce the expansion of its nationally recognized Food, Drug, Medical Device & Cosmetic practice with the addition of Partner Deborah M. Shelton.
Arent Fox Counsel Brian Malkin was quoted in a recent Pink Sheet analysis about the Food and Drug Administration (FDA)’s new efforts at transparency in the generic drug space.
FDA Announces April 25 Webinar on Genome Editing in Animals, Signaling Commitment to Implementing its Plant and Animal Biotechnology Innovation Action Plan
The Action Plan is intended to clarify the agency’s science- and-risk-based approach to regulating such products with the stated goals of fostering innovation, enhancing public communication and outreach, and increasing coordination between FDA and its federal and international counterparts.
Last week, USDA’s Agricultural Marketing Service convened a webinar to accept public comments on implementing the hemp provisions included in the 2018 farm bill.
While he did not use a hemp pen like the one used by Senate Majority Leader Mitch McConnell (R-KY) to sign the conference report, President Trump signed into law the 2018 farm bill that includes a provision that legalizes hemp. Specifically, the provision would remove hemp from the federal list of c
Arent Fox FDA Associate Emily Leongini will present at CBI’s Bio/Pharma Compliance Congress on Non-promotional Activities.
Partner Karen Carr and Associate Emily Leongini will participate as speakers at the 3rd Annual Dietary Supplement Regulatory Strategy Conference in December 2018.
NEW YORK – Earlier this year, Yeshiva University’s Katz Graduate Business School introduced a new 36-credit Master of Science in Biotechnology Management and Entrepreneurship designed to prepare future business leaders in the life sciences to successfully navigate the launching new medical drugs.
Brian Ronholm, Senior Director of Regulatory Policy, and Emily Leongini, Associate, will present at FoodSafety Tech's 2018 Food Safety Consortium.
Byron Dorgan, Philip S. English*, Dan H. Renberg, Jon S. Bouker, Craig Engle, Norman F. Lent III, Laura E. Doyle, Mariana Acuna*, Daniel Sjostedt*
As the dust settles on a campaign cycle that was unprecedented in many ways, we have composed this biennial post-election analysis to assist our clients in assessing the potential impact of the elections on their organizations and their industries.